Last reviewed · How we verify
NCT04497272: SignCov
Assesment of the Metabolomic Signature in COVID-19 Patients
NA trial testing COVID-19 patients in COVID 19 in 150 participants. Completed in 31 July 2022.
1 March 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 150 |
| Start date | 7 August 2020 |
| Primary completion | 1 March 2021 |
| Estimated completion | 31 July 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- COVID-19 patients
Conditions studied
- COVID 19 — all drugs for COVID 19 →
Sponsor
Centre Hospitalier Universitaire de Nice
Who can join
18 and older, any sex, with COVID 19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04497272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COVID-19 patients
Trials testing the same drug.
- NCT04385017 — Role of Inflammasomes in COVID-19 Disease · NA · completed
Other recruiting trials for COVID 19
Currently open trials in the same condition.
- NCT06871293 — Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19 · NA · recruiting
- NCT06599658 — COVID-19 Booster and IIV Schedule in Immunocompromised Hosts · Phase 2 · recruiting
- NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
- NCT04522076 — Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acq · active not recruiting
- NCT06702540 — Bio-reconfigurable Electronic Platform for Multiplex Detection of Viral Respiratory Pathogens · active not recruiting
Other Centre Hospitalier Universitaire de Nice trials
Trials by the same sponsor.
- NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
- NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
- NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04497272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
- Last refreshed: 31 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04497272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing